International Business Magazine Headquarters in India

Promise of Eli Lilly’s weight-loss drug for sleep apnea provides yet every other motive to possess the stock

Promise of Eli Lilly’s weight-loss drug for sleep apnea provides yet every other motive to possess the stock

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York Metropolis on Dec. 11, 2023.

Brendan Mcdermid | Reuters

Eli Lilly‘s weight-loss drug Zepbound showed promise as a medication for sleep apnea — giving investors more confidence to take care of proudly owning the realm’s most necessary properly being-care company even after or no longer it has been crushing the S&P 500’s efficiency all by scheme of the last three years.

Shruthi M is a dedicated Business News Reporter at Global Business Line, specializing in breaking stories, insightful analyses, and comprehensive coverage of the global business landscape. With a keen eye for detail and a passion for delivering accurate and timely news, Shruthi keeps readers informed on the latest market trends, corporate strategies, and economic developments shaping industries worldwide.


Discover more from GLOBAL BUSINESS LINE

Subscribe to get the latest posts sent to your email.

Discover more from Global Business Line

Subscribe now to keep reading and get access to the full archive.

Continue reading